A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226

被引：0
|
作者：
Mehta, Rita S.
Barlow, William E.
Albain, Kathy S.
Vandenberg, Ted A.
Dakhil, Shakher R.
Tirumali, Nagendra L.
Lew, Danika L.
Hayes, Daniel F.
Gralow, Julie R.
Linden, Hannah M.
Livingston, Robert B.
Hortobagyi, Gabriel N.
机构：
[1] UCIMC, Orange, CA USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Wichita Community Clin Oncol, Wichita, KS USA
[6] Northwest CCOP Northwest, Portland, OR USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Puget Sound Canc Consortium, Seattle, WA USA
[9] Univ Washington, Seattle, WA 98195 USA
[10] Univ Arizona, Arizona Canc, Tucson, AZ USA
[11] MD Anderson, Houston, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-07
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: Methodologic issues
    Winquist, E
    Bramwell, V
    Vandenberg, T
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3748 - 3749
  • [32] Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
    Robertson, John F. R.
    Lindemann, Justin P. O.
    Llombart-Cussac, Antonio
    Rolski, Janusz
    Feltl, David
    Dewar, John
    Emerson, Laura
    Dean, Andrew
    Ellis, Matthew J.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) : 503 - 511
  • [33] Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
    John F. R. Robertson
    Justin P. O. Lindemann
    Antonio Llombart-Cussac
    Janusz Rolski
    David Feltl
    John Dewar
    Laura Emerson
    Andrew Dean
    Matthew J. Ellis
    Breast Cancer Research and Treatment, 2012, 136 : 503 - 511
  • [34] Double-blind, Randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
    Osborne, CK
    Pippen, J
    Jones, SE
    Parker, LM
    Ellis, M
    Come, S
    Gertler, SZ
    May, JT
    Burton, G
    Dimery, I
    Webster, A
    Morris, C
    Elledge, R
    Buzdar, A
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) : 3386 - 3395
  • [35] Anastrozole ('arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind crossover SAKK Trial 21/95 - a sub-study of Anastrozole Trial 0027.
    Thuerlimann, B
    Hess, D
    Koeberle, D
    Senn, I
    Ballabeni, P
    Pagani, O
    Perey, L
    Aebi, S
    Rochlitz, C
    Goldhirsch, A
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S73 - S73
  • [36] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer:: Methodologic issues -: In Reply
    Bonneterre, J
    Nabholtz, JM
    Budzar, A
    Robertson, J
    Thürlimann, B
    Steinberg, M
    Webster, A
    von Euler, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3749 - 3750
  • [37] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    Bonneterre, J
    Thürlimann, B
    Robertson, JFR
    Krzakowski, M
    Mauriac, L
    Koralewski, P
    Vergote, I
    Webster, A
    Steinberg, M
    von Euler, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
  • [38] Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
    Binghe Xu
    Zefei Jiang
    Zhimin Shao
    Jiayu Wang
    Jifeng Feng
    Shuping Song
    Zhendong Chen
    Kangsheng Gu
    Shiying Yu
    Yiping Zhang
    Chuan Wang
    Fengchun Zhang
    Junlan Yang
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 223 - 230
  • [39] Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial
    Xu, Binghe
    Jiang, Zefei
    Shao, Zhimin
    Wang, Jiayu
    Feng, Jifeng
    Song, Shuping
    Chen, Zhendong
    Gu, Kangsheng
    Yu, Shiying
    Zhang, Yiping
    Wang, Chuan
    Zhang, Fengchun
    Yang, Junlan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 223 - 230
  • [40] Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
    Goss, Paul E.
    Ingle, James N.
    Pritchard, Kathleen I.
    Ellis, Matthew J.
    Sledge, George W.
    Budd, G. Thomas
    Rabaglio, Manuela
    Ansari, Rafat H.
    Johnson, David B.
    Tozer, Richard
    D'Souza, David P.
    Chalchal, Haji
    Spadafora, Silvana
    Stearns, Vered
    Perez, Edith A.
    Liedke, Pedro E. R.
    Lang, Istvan
    Elliott, Catherine
    Gelmon, Karen A.
    Chapman, Judy-Anne W.
    Shepherd, Lois E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1398 - 1404
12345